Evidence map›Paper›PMID 36996857›Full record

SynthesisThe Lancet. Global health2023

Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.

Louisa Degenhardt, Paige Webb, Samantha Colledge-Frisby, Jeremy Ireland, Alice Wheeler, Sophie Ottaviano, Alex Willing, Abe Kairouz, Evan B Cunningham, Behzad Hajarizadeh and 9 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in The Lancet. Global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 8 pooled it
52.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 8 syntheses or guidelines pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Circumcision for HIV Prevention in Men Who Have Sex With Men: An Updated Meta-Analysis.Journal of acquired immune deficiency syndromes (1999) · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Louisa DegenhardtNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. Electronic address: l.degenhardt@unsw.edu.au.
Paige WebbNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Samantha Colledge-FrisbyNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia; National Drug Research Institute Melbourne, Curtin University, Melbourne, VIC, Australia.
Jeremy IrelandNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Alice WheelerKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Sophie OttavianoNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Alex WillingKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Abe KairouzKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Evan B CunninghamKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Behzad HajarizadehKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Janni LeungNational Centre For Youth Substance Use Research, University of Queensland, St Lucia, QLD, Australia.
Lucy T TranNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Olivia PriceNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Amy PeacockNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Peter VickermanPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Michael FarrellNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia.
Gregory J DoreKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Matthew HickmanPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Jason GrebelyKirby Institute, University of New South Wales, Sydney, NSW, Australia.
UNSW Sydney · AUUniversity of Bristol · GBUniversity of Queensland · AU

Funding

Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modelingR01AI147490 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA · 2019 to 2022
$2.3M
Modeling Structural HIV Determinants in Substance Users and related populationsR01DA037773 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA, STRATHDEE, STEFFANIE A. · 2015 to 2017
$1.4M
Department of HealthMedical Research Council MR/N00616X/1NIAID NIH HHS R01 AI147490NIDA NIH HHS R01 DA037773
6 · The paper itself

Abstract

backgroundPeople who inject drugs are exposed to various and changing risk environments and are at risk of multiple harms related to injecting drug use (IDU). We aimed to undertake a global systematic review of the prevalence of IDU, key IDU-related harms (including HIV, hepatitis C virus [HCV], and hepatitis B virus [HBV] infection and overdose), and key sociodemographic characteristics and risk exposures for people who inject drugs.

methodsWe systematically searched for data published between Jan 1, 2017, and March 31, 2022, in databases of peer-reviewed literature (MEDLINE, Embase, and PsycINFO) and grey literature as well as various agency or organisational websites, and disseminated data requests to international experts and agencies. We searched for data on the prevalence, characteristics, and risks of people who inject drugs, including gender, age, sexuality, drug-use patterns, HIV, HCV, and HBV infections, non-fatal overdose, depression, anxiety, and injecting-related disease. Additional data were extracted from studies identified in our previous review. Meta-analyses were used to pool the data where multiple estimates were available for a country. We present country, regional, and global estimates for each variable examined.

findingsWe screened 40 427 reports published between 2017 and 2022, and the 871 eligible reports identified were added to the 1147 documents from the previous review. Evidence of IDU was documented in 190 of 207 countries and territories, and 14·8 million people (95% uncertainty interval [UI] 10·0-21·7) aged 15-64 years globally were estimated to inject drugs. Existing evidence suggests that there might be 2·8 million (95% UI 2·4-3·2) women and 12·1 million (95% UI 11·0-13·3) men who inject drugs globally, and that 0·4% (95% CI 0·3-1·3) of people who inject drugs identify as transgender. The amount of available data on key health and social risks among people who inject drugs varied widely across countries and regions. We estimated that 24·8% (95% CI 19·5-31·6) of people who inject drugs globally had experienced recent homelessness or unstable housing, 58·4% (95% CI 52·0-64·8) had a lifetime history of incarceration, and 14·9% (95% CI 8·1-24·3) had recently engaged in sex work, with substantial geographical variation. Injecting and sexual risk behaviour varied considerably geographically, as did risks of harms. Globally, we estimated that 15·2% (95% CI 10·3-20·9) of people who inject drugs are living with HIV, 38·8% (95% CI 31·4-46·9) have current HCV infection, 18·5% (95% CI 13·9-24·1) have recently overdosed, and 31·7% (95% CI 23·6-40·5) have had a recent skin or soft tissue infection.

interpretationIDU is being identified in a growing number of countries and territories that comprise more than 99% of the global population. IDU-related health harms are common, and people who inject drugs continue to be exposed to multiple adverse risk environments. However, quantification of many of these exposure and harms is inadequate and must be improved to allow for better targeting of harm-reduction interventions for these risks.

fundingAustralian National Health and Medical Research Council.

Indexed as

Drug UsersHepatitis BHepatitis CHIV InfectionsSubstance Abuse, IntravenousSubstance-Related DisordersAustraliaFemaleHepacivirusHepatitis B virusHumansMalePrevalence

Identifiers

PMID36996857
PMCPMC12580156
OpenAlexW4360991446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.